Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions
Dr Joel Neal - Stanford University, Stanford, USA
18 Jun 2019
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSC...
Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spai...
11 Jun 2019
Pembrolizumab increases long-term survival in patients with advanced NSCLC
Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA
11 Jun 2019
Expanding clinical trial eligibility criteria: Risks and solutions
Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA
11 Jun 2019
Carfilzomib and irinotecan in relapsed small cell lung cancer
Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA
6 Jun 2019
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients wit...
Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA
6 Jun 2019
Understanding eligibility criteria for clinical trials to increase study size
Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills,...
3 Jun 2019
Expanded clinical trial inclusion criteria would double the percentage of patien...
Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills,...
3 Jun 2019
Clinical and translational results from the NEOSTAR study: Treating early-stage ...
Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, US...
1 Jun 2019
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as tr...
Dr Edward B. Garon - UCLA, Los Angeles, USA
1 Jun 2019
Comment: The success of immunotherapy means we have to change our mindset as we ...
Dr David Graham and Dr Edward B. Garon
1 Jun 2019
Pembrolizumab is safe and effective and substantially increases overall survival...
Dr Edward B. Garon - UCLA, Los Angeles, USA
1 Jun 2019
